Sofia Zahid

Sofia Zahid

Auto-generated profile, based on publicly available information

Sofia Zahid

New York Presbyterian Brooklyn Methodist Hospital—Weill Cornell Medical College, Brooklyn, NY 11215, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
ASAngelica Singh
Angelica Singh
SZSofia Zahid
Sofia Zahid
INIlya Noginskiy
Ilya Noginskiy
TPTimothy Pak
Timothy Pak
SUSoeb Usta
Soeb Usta
UKUqba Khan
Uqba Khan
Hepatocellular carcinoma remains a leading cause of cancer-related deaths worldwide. Liver disease including cirrhosis and viral hepatitis remains among the leading causes of hepatocellular carcinoma and despite increased screening, many patients are diagnosed in the advanced stages precluding them from locoregional therapy. Therapeutic agents for advanced hepatocellular carcinoma were limited to Sorafenib for several years; however, with the emergence of molecular targeted therapies including tyrosine kinase inhibitors and vascular endothelial growth factor inhibitors, in addition to immunotherapies, the way hepatocellular carcinoma is treated has changed significantly. In this review, we summarize the key clinical trials that lead to the approval of these agents for systemic treatment of hepatocellular carcinoma and discuss the preferred sequence of treatment options as well as prospective studies for management of hepatocellular carcinoma.